Research map: Particle engineering, aerosol physics, and pulmonary deposition of single-inhaler triple ICS/LABA/LAMA therapies in obstructive airway diseases

Back to the article

Papers in this map

  1. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD · David A. Lipson · 2018 · 1300 citations · Cited by this paper
  2. Early vasopressin in septic shock: Which evidence should we trust? · 2026 · Related
  3. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD · Klaus Friedrich Rabe · 2020 · 719 citations · Cited by this paper
  4. Clarifying the lipid signal: non-HDL cholesterol, remnant cholesterol and metabolic risk in primary care · 2026 · Related
  5. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial · Alberto A. Papi · 2018 · 633 citations · Cited by this paper
  6. Left atrial enlargement without atrial fibrillation: a warning signal rather than a treatment target · 2026 · Related
  7. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials · Mona Bafadhel · 2018 · 449 citations · Cited by this paper
  8. Rethinking residual sex effects in frailty-adjusted ICU mortality · 2026 · Related
  9. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial · Jørgen Vestbo · 2017 · 443 citations · Cited by this paper
  10. Cardiac rehabilitation referral and access by country income class: Comparisons from the International Council of Cardiovascular Prevention and Rehabilitation’s 2025 Global Audit Update · 2026 · Related
  11. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial · Dave Singh · 2016 · 432 citations · Cited by this paper
  12. Beyond comorbidities: Age as an independent predictor of survival in pulmonary arterial hypertension · 2026 · Related
  13. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes · Omar Sharif Usmani · 2018 · 411 citations · Cited by this paper
  14. Clinical and prognostic significance of urinary albumin-to-creatinine ratio in heart failure: insights from the RICA-2 registry · 2026 · Related
  15. The Relationship Between Powder Inhaler Resistance and Peak Inspiratory Conditions in Healthy Volunteers — Implications for In Vitro Testing · Andrew R. Clark · 1993 · 334 citations · Cited by this paper
  16. Impact of ECOG performance status on cancer-associated thrombosis treated with DOACs: Data from a multicenter cohort study · 2026 · Related
  17. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study · Fernando J. Martínez · 2020 · 275 citations · Cited by this paper
  18. Lower incidence of venous thromboembolism in hospital-at-home patients: Do unequal detection opportunities and between-group non-equivalence affect the interpretation of the findings? Author's Reply · 2026 · Related
  19. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial · Laurie A. Lee · 2020 · 268 citations · Cited by this paper
  20. Biological therapy in Takayasu arteritis. Results from the REVAS registry · 2026 · Related
  21. β2-Agonist Therapy in Lung Disease · Mario Cazzola · 2013 · 263 citations · Cited by this paper
  22. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease · David A. Lipson · 2020 · 258 citations · Cited by this paper
  23. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma · Hartmut Derendorf · 2006 · 252 citations · Cited by this paper
  24. Carbon footprint impact of the choice of inhalers for asthma and COPD · Christer Janson · 2019 · 248 citations · Cited by this paper
  25. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials · Johann Christian Virchow Jr. · 2019 · 216 citations · Cited by this paper
  26. Inspiratory flow rates at different levels of resistance in elderly COPD patients · Wim Janssens · 2007 · 201 citations · Cited by this paper
  27. The prevalence of small airways disease in adult asthma: A systematic literature review · Omar S. Usmani · 2016 · 175 citations · Cited by this paper
  28. Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD Patients · Wilfried De Backer · 2010 · 173 citations · Cited by this paper
  29. Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study · Huib A.M. Kerstjens · 2020 · 162 citations · Cited by this paper
  30. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler · Claudio Sorino · 2020 · 133 citations · Cited by this paper
  31. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler ® in Comparison with Diskus ® and Turbohaler ® Dry Powder Inhalers · Francesca Buttini · 2015 · 115 citations · Cited by this paper
  32. “Current place of impulse oscillometry in the assessment of pulmonary diseases.” · Marcin Bednarek · 2020 · 101 citations · Cited by this paper
  33. Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung · Chantal Darquenne · 2016 · 89 citations · Cited by this paper
  34. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON) · Christian Geßner · 2020 · 84 citations · Cited by this paper
  35. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD · Sohini Ghosh · 2019 · 76 citations · Cited by this paper
  36. Comparing Lung Regions of Interest in Gamma Scintigraphy for Assessing Inhaled Therapeutic Aerosol Deposition · Martyn F. Biddiscombe · 2011 · 67 citations · Cited by this paper
  37. Dilemmas, Confusion, and Misconceptions Related to Small Airways Directed Therapy · Federico Lavorini · 2016 · 65 citations · Cited by this paper
  38. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis · Shih-Lung Cheng · 2018 · 55 citations · Cited by this paper
  39. Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects · Dave Singh · 2020 · 48 citations · Cited by this paper

Source: OpenAlex (CC0)